Recently, MiStent® Sirolimus Eluting Absorbable Polymer Coronary Stent System, the flagship product of Mixin Medtech, a subsidiary of Kossel Group, has been successfully approved for market launch by the National Medical Products Administration (NMPA) (Registration Certificate No.: GXZZ 20263130833).

MiStent® Sirolimus Eluting Absorbable Polymer Coronary Stent System was developed following Kossel Group’s complete acquisition of Micell Tech. By integrating innovative technology with China’s Intelligent Manufacturing, it provides a new clinical option for Percutaneous Coronary Intervention (PCI) that features both rapid healing and long-lasting efficacy.

Dual-Excellence Design: Balancing Healing Efficiency and Long-Term Protection
Rapid Healing: Ultra-Thin Stent for Fast Endothelialization
The domestic MiStent® Sirolimus Eluting Absorbable Polymer Coronary Stent System is built on a 64 μm ultra-thin cobalt-chromium alloy platform, thereby minimizing vessel injury. Its absorbable drug coating eliminates drug burst release and does not inhibit early endothelialization, enabling faster healing.

Long-Lasting Efficacy: Controlled Sustained Release for Full Coverage
Crystalline sirolimus achieves an extra-long 9-month sustained release, persistently inhibiting intimal hyperplasia and vascular inflammation triggered during polymer elution and absorption.

As the core product of Mixin Medtech, the market approval of MiStent® Sirolimus Eluting Absorbable Polymer Coronary Stent System further completes the company’s product portfolio in the coronary intervention field. Moving forward, the company will continue to be clinical-needs oriented, accelerate the commercialization of more high-quality medical device achievements, inject strong impetus into vascular disease diagnosis and treatment, and support the construction of the **Healthy China** initiative.